Pulmotect, Inc.
  • Home
  • About Us
    • Our Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Our Approach
    • Overview
    • Our Science
    • Our Pipeline
    • Published Journal Articles
  • News
  • Contact Us

Pulmotect’s PUL-042 Shows Promising Pre-Clinical Efficacy in Preventing Lethal Coronavirus Infection

Posted on January 27, 2020January 27, 2020 by Brenton Scott
Posted in Press Releases

Post navigation

Houston biopharmaceutical company brings on new CEO to grow company
Houston researchers test lung inhalant that could protect healthcare workers from COVID-19
Pulmotect Inc

3900 Essex Ln, Suite 575
Houston, TX 77027
Contact Us

© 2025
Pulmotect, Inc.